This has arisen from the identification of gain-of-function mutations of Nav1.7 in individuals with rare pain syndromes IEM, PEPD and the more common disorder SFN, as well as the discovery of this channel’s link to channelopathy-associated congenital insensitivity to pain. This evidence concerns the gene SCN9A and channelopathy.